Multi-target drugs to address multiple checkpoints in complex inflammatory pathologies: evolutionary cues for novel “first-in-class” anti-inflammatory drug candidates: a reviewer’s perspective

G. Mathew; M.K. Unnikrishnan

doi:10.1007/s00011-015-0851-8

Multi-target drugs to address multiple checkpoints in complex inflammatory pathologies: evolutionary cues for novel “first-in-class” anti-inflammatory drug candidates: a reviewer’s perspective

G. Mathew
, M.K. Unnikrishnan

Research output: Contribution to journal › Article › peer-review

Original language	Undefined/Unknown
Pages (from-to)	747-752
Number of pages	6
Journal	Inflammation Research
Volume	64
Issue number	10
DOIs	https://doi.org/10.1007/s00011-015-0851-8
Publication status	Published - 2015
Externally published	Yes

Access to Document

10.1007/s00011-015-0851-8

https://www.scopus.com/inward/record.uri?eid=2-s2.0-84941420462&doi=10.1007%2fs00011-015-0851-8&partnerID=40&md5=76e14d197452c6544cbff4f8b52c35cb

Cite this

@article{146b8beb07ed44f294f662602f3d52ab,

title = "Multi-target drugs to address multiple checkpoints in complex inflammatory pathologies: evolutionary cues for novel “first-in-class” anti-inflammatory drug candidates: a reviewer{\textquoteright}s perspective",

author = "G. Mathew and M.K. Unnikrishnan",

note = "cited By 1",

year = "2015",

doi = "10.1007/s00011-015-0851-8",

language = "Undefined/Unknown",

volume = "64",

pages = "747--752",

journal = "Inflammation Research",

issn = "1023-3830",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "10",

}

TY - JOUR

T1 - Multi-target drugs to address multiple checkpoints in complex inflammatory pathologies: evolutionary cues for novel “first-in-class” anti-inflammatory drug candidates: a reviewer’s perspective

AU - Mathew, G.

AU - Unnikrishnan, M.K.

N1 - cited By 1

PY - 2015

Y1 - 2015

U2 - 10.1007/s00011-015-0851-8

DO - 10.1007/s00011-015-0851-8

M3 - Article

SN - 1023-3830

VL - 64

SP - 747

EP - 752

JO - Inflammation Research

JF - Inflammation Research

IS - 10

ER -